Skip to content

Providing Rapid Out of Hospital Acute Cardiovascular Treatment (PROACT)

Providing Rapid Out of Hospital Acute Cardiovascular Treatment (PROACT) Novel Proximal Pathways for Non ST Elevation Myocardial Infarction

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01634425
Acronym
PROACT
Enrollment
601
Registered
2012-07-06
Start date
2011-11-30
Completion date
2015-02-28
Last updated
2015-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSTEMI

Keywords

NSTEMI, Point of Care Biomarkers

Brief summary

The purpose of this study is to determine if early diagnosis and risk stratification acquired through pre-hospital clinical assessment, 12-lead electrocardiogram and point of care biomarkers will facilitate enhanced triage and treatment in patients with presumed non-ST elevation acute coronary syndromes (NSTEMI).

Detailed description

Utilizing the platform of pre-hospital STEMI research and clinical experience developed over the past decade; we now intend to investigate how best to achieve timely diagnosis and risk stratification of patients that present to pre-hospital emergency medical services with symptoms suspicious for acute NSTEMI through utilization of systematic clinical assessment, pre-hospital 12 lead electrocardiogram and point of care measurement of biomarkers. Additionally, where deemed appropriate these patients will be enrolled in a clinical Chest Pain Protocol utilizing the pre-hospital biomarkers. We hypothesize that establishing a pre-hospital diagnosis in this condition may facilitate efficient triage and -as appropriate- in-hospital disposition. Additionally, the enhanced pre-hospital assessment of this population will facilitate appropriate timely disposition of those patients not found to have acute cardiovascular disease. These processes will facilitate decanting the frequently overcrowded and under resources Emergency Departments.

Interventions

DEVICEAlere Triage Meter Pro

Troponin and BNP measured on point of care meter.

Sponsors

Canadian VIGOUR Centre
CollaboratorOTHER
University of Alberta
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
31 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patient that activates pre-hospital Emergency Medical Services (EMS) for symptoms of acute chest discomfort for which acute cardiovascular disease is deemed to be the most probable diagnosis by EMS personnel. 2. Patient is older than 30 years of age 3. Patient is able to give informed consent

Exclusion criteria

1. Patient with documented ST elevation on the initial 12 lead ECG 2. Patient with a prior diagnosis that is compatible with another disease i.e. severe asthma, etc. 3. Patient with Central Nervous System symptoms or syncope 4. Patient with cardiac arrest, ventricular tachycardia or atrial fibrillation with heart rate \> 110 bpm

Design outcomes

Primary

MeasureTime frameDescription
Time from first medical contact to final patient disposition.From date of first medical contact until first appropriate therapy given, assessed up to 30 monthsAn Adjudication Committee will examine the records to determine final diagnosis. Final patient disposition is defined as the time when a plan for patient discharge from the ED or admission to hospital is both established and documented.

Secondary

MeasureTime frameDescription
Length of hospital stay for patients admitted to hospitalAssessed up to 30 months
In-hospital clinical events (day 7 or discharge) all-cause mortality, cardiogenic shock, heart failure, re-Myocardial infarctionAssessed up to 30 months
30-day all-cause mortalityAssessed up to 30 months
30 day all-cause hospitalization or re-hospitalizationAssessed up to 30 months
30-day composite (all-cause mortality or all-cause hospitalization)Assessed up to 30 months
Time to administration of appropriate evidence based therapyAssessed up to 30 months.From time of first medical contact to First appropriate therapy for NSTEMI is defined as: receiving oral antiplatelet agent (excluding ASA - which is routinely administered prior to diagnosis) or intravenous/subcutaneous antithrombotic agents (low molecular weight heparin or IV heparin or glycoprotein IIb/IIIa receptor inhibitors).

Other

MeasureTime frame
Explore the incremental value pre-hospital BNP on primary and secondary endpoints.Assessed up to 30 months

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 13, 2026